Figgs, Since you don't like 18 months, what time f
Post# of 154858
(Total Views: 533)
Posted On: 11/05/2024 7:18:27 AM
Figgs, Since you don't like 18 months, what time frame would get you to stop your f-bombing of another's opinion?
I type as a late 2015 long, beaten down by the years, now in a position on the ground like my older brothers used to put me in, even after crying uncle.
Our current work in Glioblastoma is in a mouse model. Not a needle mover, but good that they've seen signals making it worth a try. So many companies have and are chasing glio. That includes RestorGenex, whose CEO Stephen Simes is now on our BOD. He 'advanced several therapeutics'. Nothing approved. My accountant said it was a loss for me, not the 'delivered shareholder value' noted on our website. (Shareholder means company founders, management team and placement agent - edit by Cap'n Obvious).
Much more exciting to me that we're trying to help real humans with CRC and Alzheimer's. Those results are a ways out, as posted by others.
Biotech investors seem fickle and impatient, as if they don't know that good Phase II results often lead to a longer pivotal Phase III trial. So many companies get a price pop on good data, then a slow or fast slide back down to baseline. It's a slog, even though Leronlimab is safe and even though we're trying to help people.
As a '15er, I feel like there's been plenty of time for "someone with money" (your words) to jump in and grab us. So now, our management team has been re-created, and we'll be out here on our own a bit longer (we = all 1000-ish of us shareholders). IMO.
I type as a late 2015 long, beaten down by the years, now in a position on the ground like my older brothers used to put me in, even after crying uncle.
Our current work in Glioblastoma is in a mouse model. Not a needle mover, but good that they've seen signals making it worth a try. So many companies have and are chasing glio. That includes RestorGenex, whose CEO Stephen Simes is now on our BOD. He 'advanced several therapeutics'. Nothing approved. My accountant said it was a loss for me, not the 'delivered shareholder value' noted on our website. (Shareholder means company founders, management team and placement agent - edit by Cap'n Obvious).
Much more exciting to me that we're trying to help real humans with CRC and Alzheimer's. Those results are a ways out, as posted by others.
Biotech investors seem fickle and impatient, as if they don't know that good Phase II results often lead to a longer pivotal Phase III trial. So many companies get a price pop on good data, then a slow or fast slide back down to baseline. It's a slog, even though Leronlimab is safe and even though we're trying to help people.
As a '15er, I feel like there's been plenty of time for "someone with money" (your words) to jump in and grab us. So now, our management team has been re-created, and we'll be out here on our own a bit longer (we = all 1000-ish of us shareholders). IMO.
(14)
(0)